Microporous annealed particle scaffold integrated with autologous tumor cells for personalized postsurgical tumor therapy.
An autologous tumor cell-integrated microporous annealed particle scaffold co-delivering an immune adjuvant and an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor for tumor postoperative therapy is developed, establishing a paradigm that unifies personalized immunotherapy with personalized tissue repair, offering substantial promise for postsurgical cancer therapy.